A trial looking at immunotherapy for people with some types of blood cancer using CAR T-cells (ALLCAR19)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Acute leukaemia

Acute lymphoblastic leukaemia (ALL)

Blood cancers

Chronic leukaemia

Chronic lymphocytic leukaemia (CLL)

High grade lymphoma

Hodgkin lymphoma

Leukaemia

Low grade lymphoma

Lymphoma

Non-Hodgkin lymphoma

Status:

Closed

Phase:

Phase 1

This trial is looking at changing immune cells to recognize and attack cancer cells. The changed immune cells are called CD19CAR T-cells.

It is for people who have either:

acute lymphoblastic leukaemia with a high risk of it coming back after treatment (high risk ALL) or ALL that has come back after treatment (relapsed)
certain types of slow growing (low grade) non-Hodgkin lymphoma
diffuse large B cell lymphoma (DLBCL)
chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
follicular lymphoma
mantle cell lymphoma

Please note that this trial is currently only recruiting people who have mantle cell lymphoma (MCL).

More about this trial

The CD19CAR T-cell treatment is a type of gene therapy that uses a type of white blood cells called T cells. These cells are part of your immune system. T cells are very good at fighting infection but not so good at recognising and attacking cancer cells.

In this trial, doctors use your own T cells to make the CD19CAR T-cell treatment. Doctors will take some of your white cells using a procedure called leucapheresis.

They grow your white cells in the laboratory alongside a virus called lentivirus. The lentivirus has been changed so it can’t cause an infection. The lentivirus has a gene that can recognise a protein called CD19. Some cancer cells have a high number of CD19 proteins on their surface.

Doctors hope that this gene will be passed on to your T cells. So, when you have the changed T cells back (the CD19CAR T-cells treatment), they recognise and attack the cancer cells.

The main aims of this trial are to learn more about this type of treatment, how well it works and its side effects.

Who can enter

The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.

Who can take part
You may be able to join this trial if you have 1 of the following types of blood cancer:

diffuse large B cell lymphoma (DLBCL)
chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
mantle cell lymphoma
follicular lymphoma

Your doctor checks your past treatments to see if you are suitable to join the trial.

As well as the above, the following must also apply.

your cancer cells have the protein CD19 on the surface (your doctor will check for this)
you have satisfactory blood tests results
doctors think you can have leucapheresis
you are at least 16 old
you might need help but can mostly care for yourself (Karnofsky performance status 60 and above)
you are willing to use reliable contraception during treatment and for a year afterwards

Who can’t take part
You cannot join this trial if any of these apply.

Cancer related
You:

have cancer that has spread to your brain or spinal cord
have cancer outside the bone marrow (intramedullary) if you have CLL
developed a condition called graft versus host disease (GVHD) after having a donor transplant (stem cell transplant), and this is causing you moderate or severe problems

Medical conditions
You:

have breathing problems, the amount of oxygen in your blood (oxygen saturation) is lower than 90% or you need oxygen therapy
have problems with the rhythm of your heart (uncontrolled arrhythmias) or any other significant heart problems
have problems with your brain, spinal cord and nerves
have an infection
have HIV
have active hepatitis B or hepatitis C (you will be able to take part if you have had these conditions in the past)

Other
You:

are allergic to albumin or dimethyl sulfoxide (DMSO)
are pregnant or breastfeeding

As well as the above there are other specific exclusion criteria for people who have DLBCL. Speak to your doctor or research nurse if you want to find out more about this.

Trial design

This is a phase 1 trial. The researchers need around 60 people to take part.

Everyone has treatment with CD19CAR T cells. There are 3 steps to your treatment:

leucapheresis
lymphodepletion
CD19CAR T-cells drip

Leucapheresis
Leucapheresis means having white blood cells removed from your bloodstream.

You lie on a bed or reclining chair and have a tube put into a vein in each arm. One tube removes blood and passes it into a machine that removes white blood cells. The rest of your blood cells and blood fluid (plasma) go back into your body through the tube in your other arm.

The white cells are taken to the laboratory and grown alongside the lentivirus. Growing the white cells in the laboratory might not always work. Your doctor will talk to you about this and about what other treatments that might be available, if this happens.

Lymphodepletion
A week before you have the CD19CAR T-cells drip, you have chemotherapy. This helps the CD19CAR T-cells to grow in your body.

You have:

cyclophosphamide as a drip into your bloodstream once
fludarabine as a drip into your bloodstream once a day, for 3 days

As well as the above, you also have 1 dose of pembrolizumab if you have DLBCL. You have this the day before the CD19CAR T-cells drip. It takes about 30 minutes.

CD19CAR T-cells drip

You have the changed white cells (CD19CAR T-cells) as a drip into your bloodstream. You have it as 1 dose if you have DLBCL. You have it as 2 separate doses if you have CLL or SLL. It takes about 30 minutes each time you have it.

ALLCAR19 Trial Diagram

Hospital visits

You see a doctor and have some tests before taking part. These tests might include:

a physical examination
blood tests
bone marrow test
lumbar puncture
lymph node biopsy
CT scan or PET-CT scan

You go to hospital to have leucapheresis. This is done as a day case. It takes about 2 weeks for the changed T cells to be made in the laboratory. Your doctor or nurse will tell you when you need to go back to the hospital to have chemotherapy. And when you have pembrolizumab if you have DLBCL.

You see a doctor before having the CD19CAR T-cells treatment and have:

a physical examination
blood tests
bone marrow test
CT scan or PET-CT scan

You might also need to give a sample of your lymph node.

You stay in hospital for some time after having the CD19CAR T-cells treatment. You have regular blood tests, physical examinations and scans. Your doctor will tell you how long you need to stay in hospital for. It can be for up to 2 weeks.

You may be able to stay in a hotel close to the hospital if you are well enough. Your doctor will talk to you about this.

After treatment, you see the doctor every 4 weeks for 6 months. You then see them:

every 6 weeks for 6 months
every 3 months for a year
then every year for up to 8 years

Quality of life
The study team will ask you to fill out a questionnaire before you start treatment and at set times during follow up of the treatment. The questionnaire asks about side effects and how you’ve been feeling. This is called a quality of life study.

Side effects

Your doctor will talk to you about the possible side effects of all the treatment before you agree to take part in this trial.

Leucapheresis is a safe procedure and most people don’t have side effects. The side effects might include:

feeling lightheaded
a drop in the level of calcium in your blood causing numbness and tingling in the hands, feet and around the mouth
muscles spasms

Your doctor can give you treatment for the low level of calcium if this happens.

You might have side effects when you are having the CD19CAR T-cells drip. These might include:

high temperature (fever) and shivering
difficulty breathing
skin rash
feeling sick
a condition called cytokine release syndrome (CRS) – symptoms of CRS can be mild (fever and muscle ache), moderate (such as low blood pressure and difficulty breathing), or severe (can cause death)
confusion and difficulty speaking
fits (seizures)
an increased risk of getting an infection
an increased risk of having another cancer (this is rare)

In this trial only people who have DBCL have pembrolizumab. It can affect the immune system. It may cause inflammation in different parts of the body. This can cause serious side effects. They could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening.

If you have any of these side effects tell your doctor or nurse as soon as possible. You should tell them that you are on or have been on an immunotherapy.

The most common side effects of pembrolizumab are: